Form 4: Crinetics Pharmaceuticals Director Vivaldi Coelho Rogerio Reports Stock and Option Transactions

Director Vivaldi Coelho Rogerio reported the acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.

Summary

• On June 7, 2024, Vivaldi Coelho Rogerio, a director of Crinetics Pharmaceuticals, reported transactions involving the company's securities.
• Rogerio acquired 3,400 shares of common stock through restricted stock units at a price of $0.
• These restricted stock units vest 100% on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued service on the board.
• Rogerio also acquired a stock option to purchase 12,500 shares of common stock at an exercise price of $44.71, expiring on June 7, 2034.
• This stock option vests on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued service on the board.
• Following these transactions, Rogerio directly owns 14,400 shares of common stock and holds options for 12,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of stock and options suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of restricted stock units and stock options by a director signals confidence in the company's future performance.

Future Outlook

The restricted stock units and stock options vest based on continued service on the board, indicating an incentive for the director to remain with the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in the company's securities. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of compensation for directors in publicly traded companies, aligning their interests with those of shareholders.
• The vesting schedules, contingent on continued service, are typical for such grants.
• The specific terms of the grants (number of shares, exercise price, vesting schedule) would need to be compared to those of peer companies to assess their relative attractiveness.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they reflect insider confidence.

Key Dates